Back to Search
Start Over
The 5-HT2C receptor agonist lorcaserin reduces cocaine self-administration, reinstatement of cocaine-seeking and cocaine induced locomotor activity.
- Source :
-
Neuropharmacology . Feb2016, Vol. 101, p237-245. 9p. - Publication Year :
- 2016
-
Abstract
- Lorcaserin (Lorqess, Belviq ® ) is a selective 5-HT 2C receptor agonist that has received FDA approval for the treatment of obesity. 5-HT 2C receptor agonists are also efficacious in decreasing multiple aspects of cocaine motivation and reward in preclinical models. This would suggest that lorcaserin is a clinically available therapeutic with the potential to treat cocaine addiction. Here we report the effects of lorcaserin (0.1 mg/kg–1.0 mg/kg) on multiple aspects of cocaine-related behaviours in rats. We find that lorcaserin dose-dependently decreases cocaine self-administration on progressive and fixed ratio schedules of reinforcement. Lorcaserin also reduces reinstatement of cocaine-seeking behaviour in response to priming injections of cocaine and/or reintroduction of cocaine-associated cues. Finally, lorcaserin dose-dependently decreases cocaine-induced hyperlocomotion. Our results, when considered in concert with similar emergent findings in non-human primates, strongly support continued research into the potential of lorcaserin as a clinical treatment for cocaine addiction. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00283908
- Volume :
- 101
- Database :
- Academic Search Index
- Journal :
- Neuropharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 111440072
- Full Text :
- https://doi.org/10.1016/j.neuropharm.2015.09.028